Research Progress and Nonclinical Evaluation Considerations on Drugs for Duchenne Muscular Dystrophy

Rong Yi, Fu Shujun, Wang Shiqi, Rao Zijian, Sun Tao

Chinese Pharmaceutical Affairs ›› 2026, Vol. 40 ›› Issue (10) : 1260-1271.

PDF(1004 KB)
PDF(1004 KB)
Chinese Pharmaceutical Affairs ›› 2026, Vol. 40 ›› Issue (10) : 1260-1271. DOI: 10.16153/j.1002-7777.2026-08-0002
Assessment Techniques & Guidance: Special Column on Technical Assessment of Biologics

Research Progress and Nonclinical Evaluation Considerations on Drugs for Duchenne Muscular Dystrophy

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}[J]. {{journal.qiKanMingCheng_EN}}, 2026, 40(10): 1260-1271 https://doi.org/10.16153/j.1002-7777.2026-08-0002

References

List( Publishing order | Descend order by publishing year | Descend order by cited within ) Chart analysis

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(1004 KB)

Accesses

Citation

Detail
Sections
Recommended
京ICP备17052540号-7
Copyright © Chinese Pharmaceutical Affairs, All Rights Reserved.
Powered by Beijing Magtech Co. Ltd.

/

〈 〉